HAp Nano Stent Coating Shows Excellent Biocompatibility, Safety

MIV Therapeutics (MIVT) , a developer of next-generation drug-eluting coatings that inhibit the rejection of implanted medical devices, has announced the successful completion of pilot preclinical studies of hydroxyapatite (HAp) coated stents in pig coronary arteries.

The histopathology studies that followed angiographic and intravascular ultrasound evaluation confirmed excellent biocompatibility and safety of its proprietary HAp coating for vascular applications.

The 28-day safety study was performed on four different formulations of MIVT's biocompatible HAp nano-film coating specifically designed for cardiovascular stents, vascular applications and use in a broad range of other implantable medical devices. Stents coated with MIVT's proprietary coating demonstrated superb safety and healing properties when implanted in pig coronary arteries.

()a href="http://www.fdanews.com/pub/ddl"